<DOC>
	<DOC>NCT00078793</DOC>
	<brief_summary>This study will evaluate long-term safety of etanercept with or without other DMARDs in children with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared to a cohort of subjects with polyarticular or systemic JRA receiving methotrexate with or without other DMARDs.</brief_summary>
	<brief_title>Registry of Etanercept (EnbrelÂ®) In Children With Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>JRA by American College of Rheumatology (ACR) criteria Active joints Initiate etanercept alone, etanercept plus methotrexate or other DMARDs, methotrexate alone, or methotrexate with other DMARDs within 6 months of entry into Registry Polyarticular or systemic RA in 3 or more joints at start of treatment</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>JRA</keyword>
	<keyword>Registry</keyword>
</DOC>